<https://rdf.molmedb.upol.cz/reference/ref1077> <http://purl.org/dc/terms/subject> <https://rdf.molmedb.upol.cz/transporter/target78>,
		<https://identifiers.org/molmedb/MM16888>;
	<http://purl.org/ontology/bibo/pmid> "15059881"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/ontology/bibo/doi> "10.1158/0008-5472.can-03-3344"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://purl.org/dc/terms/subject> <https://identifiers.org/molmedb/MM00575>;
	<http://purl.org/dc/terms/bibliographicCitation> "Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, Traxler P.: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res, Volume 64 (7), 2004"^^<http://www.w3.org/2001/XMLSchema#string>;
	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/dc/terms/BibliographicResource> .
<https://rdf.molmedb.upol.cz/transporter/tra57188> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref1077> .
<https://rdf.molmedb.upol.cz/transporter/tra56815> <http://www.w3.org/ns/prov#hadPrimarySource> <https://rdf.molmedb.upol.cz/reference/ref1077> .